Horizon Pharma

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Last December, Amgen and Horizon agreed to a $27.8 billion buyout agreement. This proposed deal is now in doubt following a report that the FTC plans on challenging the takeover in federal court.

Why Horizon Therapeutics Stock Is Crashing Today

Amgen

The U.S. Federal Trade Commission said on Tuesday it has filed a lawsuit to stop Amgen Inc's $27.8 billion acquisition of Horizon Therapeutics Plc in a rare move to block a large pharmaceutical deal.

FTC sues to block Amgen's $27.8 billion deal for Horizon Therapeutics

The FTC is preparing to seek an injunction in federal court that would prevent the deal from closing.

FTC Poised to Block Amgen's $27.8 Billion Deal for Horizon Therapeutics

Shares of Horizon Therapeutics tumbled on Tuesday following a report that the Federal Trade Commission (FTC) is preparing to block its $27.8 billion sale to Amgen. Per a Bloomberg report citing an unnamed source familiar with the matter, the FTC could file a lawsuit to block the acquisition as soon as Tuesday.

FTC to challenge Amgen's $27.8B acquisition of Horizon Therapeutics: report

Horizon Therapeutics (NASDAQ: HZNP ) stock is sinking 18% this morning. The Federal Trade Commission (FTC) is reportedly attempting to block the drug maker's proposed merger with Amgen (NASDAQ: AMGN ).

HZNP Stock Alert: Why Is Horizon Therapeutics Plunging Today

Seagen

Prometheus Biosciences

Reports the FTC could block Amgen's takeover of Horizon reverberated across biotech stocks on Tuesday, with HZNP stock's crash leading the way. The post Horizon Tumbles — Taking Seagen, Prometheus With It — On Reports FTC Could Block Its Amgen Takeover appeared first on Investor's Business Daily.

Horizon Tumbles — Taking Seagen, Prometheus With It — On Reports FTC Could Block Its Amgen Takeover

The deal is bid to strengthen Amgen's drug portfolio as it prepares to face several patent expirations for key treatments over the next decade.

Horizon Therapeutics stock plunges on report FTC is preparing to block Amgen deal

Amgen reached an agreement to buy Horizon for $27.8 billion in December last year, and at the time said it expected the deal to be completed in the first half of 2023.

Horizon Therapeutics Stock Plunges on Reports FTC Will Sue to Block Amgen Deal

Horizon Therapeutics (HZNP) reports lower-than-expected first-quarter 2023 results as it misses the Zacks Consensus Estimates for both revenues and earnings.

Horizon (HZNP) Q1 Earnings and Revenues Miss Estimates

While the top- and bottom-line numbers for Horizon Therapeutics (HZNP) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Horizon Therapeutics (HZNP) Q1 Earnings: A Look at Key Metrics

Horizon Therapeutics (HZNP) came out with quarterly earnings of $0.83 per share, missing the Zacks Consensus Estimate of $1.17 per share. This compares to earnings of $1.34 per share a year ago.

Horizon Therapeutics (HZNP) Q1 Earnings and Revenues Lag Estimates

Alnylam Pharmaceuticals

Apellis Pharma

argenx

Ascendis Pharma

BioMarin Pharmaceutical

Amicus Therapeutics

Madrigal Pharmaceuticals

Sarepta Therapeutics

United Therapeutics

Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.

These Are the Top 10 Holdings of Avoro Capital Advisors

Airbnb

Dril-Quip

SIGA Technologies

ABNB, SIGA, DRQ, SWRAY and HZNP have been added to the Zacks Rank #1 (Strong Buy) List on April 14, 2023.

New Strong Buy Stocks for April 14th

Horizon Therapeutics (HZNP) announces positive top-line data from its phase IV study of Tepezza to expand its indication to include TED in adult patients with chronic/low clinical activity scores.

Horizon's (HZNP) Tepezza Meets Goals in TED Expanded Use Study

CSL Ltd

Humana

Novo Nordisk

The top and bottom-line growth make these Zacks Medical stocks very attractive.

5 Diverse Medical Stocks to Buy for 2023 and Beyond

Amphastar Pharma

Catalyst Pharmaceuticals

Enliven Therapeutics Inc

Vertex Pharmaceuticals

The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.

The Cream Of The Crop: 5 Biotech Stocks That Outrank 91% Of All Stocks

Altra Industrial Motion

Aramark

Bowlero Corp

Salesforce

First Horizon National

Alphabet

Liberty Broadband

Rivian Automotive

Signify Health

George Soros is considered to be among the most successful investors of all time. He managed client money from 1969 to 2011 and his Quantum Fund gave an average annual return of 30% from 1970 to 2000.

These Are the Top 10 Holdings of George Soros

Horizon Therapeutics (HZNP) possesses solid growth attributes, which could help it handily outperform the market.

3 Reasons Growth Investors Will Love Horizon Therapeutics (HZNP)

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Horizon Therapeutics (HZNP) is a Strong Growth Stock

Accenture Plc

Aptiv Holdings Ltd

Eaton

Medtronic

Ahead of St. Patrick's Day, when everyone is Irish for a day, investors may be interested in trying their luck with companies headquartered on the Emerald Isle.

5 Stocks Gurus Are Trying Their Luck With for St. Patrick's Day

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new MRI imaging data from the Phase 3 clinical trial showing UPLIZNA reduced the formation of subclinical (asymptomatic) optic nerve lesions in people with NMOSD. These findings are being presented during the 49th annual meeting of the North American Neuro-Ophthalmology Society (NANOS) March 11-16, 2023, in Orlando, Florida.

New Analysis of MRI Findings Show UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Asymptomatic Optic Nerve Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Horizon Therapeutics (HZNP) reports better-than-expected fourth-quarter 2022 results as it beats the Zacks Consensus Estimate for both revenues and earnings.

Horizon's (HZNP) Q4 Earnings and Revenues Surpass Estimates

While the top- and bottom-line numbers for Horizon Therapeutics (HZNP) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Horizon Therapeutics (HZNP) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 11.01% and 1.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Horizon Therapeutics (HZNP) Q4 Earnings and Revenues Top Estimates

Horizon Therapeutics Public Limited Company is a $25 billion biotech that's being acquired by Amgen Inc. The FTC has issued a 2nd request following a letter by Senator Elizabeth Warren.

Horizon Therapeutics: Attractive 5.4% Upside To Amgen Offer

News for Horizon Pharma Stock (HZNP)